Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
Yoshihiro Shibata, Hirofumi Ohmura, Kazuki Komatsu, Kosuke Sagara, Atsuji Matsuyama, Ryuji Nakano, Eishi Baba
BACKGROUND: Metastatic cardiac tumors are known to occur more frequently than primary cardiac tumors, however, they often remain asymptomatic and are commonly discovered on autopsy. Malignant tumors with a relatively high frequency of cardiac metastasis include mesothelioma, melanoma, lung cancer, and breast cancer, whereas reports of esophageal cancer with cardiac metastasis are rare. CASE SUMMARY: The case of a 60-year-old man who complained of dysphagia is presented...
March 21, 2024: World Journal of Gastroenterology: WJG
#22
Kentaro Suzuki, Yoshiro Kai, Ryosuke Kataoka, Maiko Takeda, Shigeo Muro
Sarcoidosis is a multisystemic granulomatous disease that is frequently localized in the lungs and lymph nodes. We herein report a case of pulmonary sarcoidosis secondary to shin'iseihaito administration. During remission with 5 mg prednisolone/day of maintenance treatment, chest computed tomography revealed a mass in the left lower lobe with re-enlarged bilateral hilar/mediastinal lymph nodes. Transbronchial lung biopsy of the mass and endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal lymph nodes revealed adenocarcinoma and noncaseating granulomas, respectively...
April 2024: Respirology Case Reports
#23
Xiang Tan, Zuotao Wu, Mingwu Chen
Previous case reports have demonstrated the effectiveness of combination therapy involving EGFR TKI, BRAF inhibitor dabrafenib, and MEK inhibitor trametinib in metastatic non-small-cell lung cancer (NSCLC) patients with acquired BRAF V600E and EGFR mutations. However, the current literature does not provide any reports on the presence of resistant mutations in response to the administration of three-drug combination therapy. Exploring the resistance mechanism of targeted therapy is helpful to optimize the subsequent treatment strategy of patients...
2024: OncoTargets and Therapy
#24
JOURNAL ARTICLE
Ali Chour, Clémence Basse, Fanny Lebossé, Pierre-Emmanuel Bonte, Nicolas Girard, Michaël Duruisseaux
INTRODUCTION: Sotorasib is a first-in-class KRASG12C inhibitor that showed significant clinical activity in KRASG12C -mutated non-small cell lung cancer (NSCLC). The most frequent grade 3 or 4 sotorasib-related adverse events (AEs) were diarrhea (4-12 %) and hepatotoxicity (10.1-15.1 %). Data is lacking about the management of these AEs, especially in patients receiving sequential anti-PD-(L)1 and sotorasib therapy. Our aim was to report the management of grade ≥ 2 sotorasib-related AEs in real-world setting and to propose practical guidance for the management of grade ≥ 2 sotorasib-related AEs and more generally KRASG12C inhibitors-related AEs...
April 9, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
#25
REVIEW
Guixin Ding, Tianqi Wang, Hongquan Liu, Qingsong Zou, Jitao Wu
Adenoid cystic carcinoma (ACC), a rare malignancy, typically originates in salivary glands and is rarely found in other locations. In this case report, we describe a 54-year-old male patient who was presented to the Urology Department of Yantai Yuhuangding hospital with right-sided waist pain. The patient underwent percutaneous ultrasound-guided biopsies of lesions in the kidney and lung, which were histologically confirmed as primary adenoid cystic carcinoma of the lung and metastatic renal adenoid cystic carcinoma, respectively...
2024: American Journal of Men's Health
#26
JOURNAL ARTICLE
Oliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Sayed M S Hashemi, Urska Janzic, Waleed Kian, Katja Mohorcic, Saara Mohammed, Maria Silvoniemi, Sacha I Rothschild, Christian Schulz, Claas Wesseler, Alfredo Addeo, Karin Armster, Malinda Itchins, Marija Ivanović, Diego Kauffmann-Guerrero, Jussi Koivunen, Jonas Kuon, Nick Pavlakis, Berber Piet, Martin Sebastian, Janna-Lisa Velthaus-Rusik, Luciano Wannesson, Marcel Wiesweg, Robert Wurm, Corinna Albers-Leischner, Daniela E Aust, Melanie Janning, Hannah Fabikan, Sylvia Herold, Anna Klimova, Sonja Loges, Yana Sharapova, Maret Schütz, Christoph Weinlinger, Arschang Valipour, Tobias Raphael Overbeck, Frank Griesinger, Marko Jakopovic, Maximilian J Hochmair, Martin Wermke
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab...
April 3, 2024: International Journal of Molecular Sciences
#27
JOURNAL ARTICLE
Christer Ruff, Paula Bombach, Georg Gohla, Till-Karsten Hauser, Frank Paulsen, Nick Farhang, Hans Boesmueller, Rudi Beschorner, Malte Bongers
A 61-year-old patient was diagnosed with a left-sided falx meningioma. Histopathological analysis following extirpation showed a meningothelial meningioma ZNS WHO grade 1 with sparse mitoses. Over the course of 12 years, the patient received irradiation (54.0 Gy), peptide radio-receptor therapy (177 Lu-DOMITATE) and targeted therapy (mTOR inhibitor). Follow-up imaging revealed an increased size of the residual tumor. Due to increased liver function parameters, imaging of the liver was performed, showing widespread space-occupying lesions with atypical appearance...
March 22, 2024: Diagnostics
#28
Nicoletta Mancianti, Sergio Antonio Tripodi, Alessandra Pascucci, Marta Calatroni, Edoardo La Porta, Andrea Guarnieri, Guido Garosi
Introduction : The combination therapy of platinum and pembrolizumab looks like a promising treatment in advanced non-small-cell lung cancer. However, both platinum-based chemotherapy and pembrolizumab can lead to AKI. AKI can occur due to acute tubular necrosis or interstitial nephritis. It is essential to identify the drug responsible for renal damage. For this purpose, we used new immunohistochemistry markers (p53 and anti-PD1 analysis). Case Description : A 77-year-old female patient with advanced non-small-cell lung cancer received the PD-1 inhibitor pembrolizumab and platinum-based chemotherapy carboplatin...
March 22, 2024: Journal of Clinical Medicine
#29
JOURNAL ARTICLE
Yang-Ming Lee, Yuag-Meng Liu, Tsung-Chia Chen
BACKGROUND: Cryptococcal osteomyelitis is a rare and potentially serious condition, typically encountered in individuals with compromised immune systems. This case underscores the unusual occurrence of disseminated Cryptococcosis in an immunocompetent person, involving multiple bones and lungs, with Cryptococcus neoformans identified as the causative agent. CASE PRESENTATION: An Indonesian man, previously in good health, presented with a chief complaint of successive multiple bone pain lasting for more one month, without any prior history of trauma...
April 12, 2024: BMC Infectious Diseases
#30
Ingitha Pulikkal, Mahadev Meena, Garima Goel, Abhishek Goyal, Tanya Sharma
Solitary fibrous tumor (SFT) of the lung is a rare mesenchymal neoplasm of uncertain histogenesis, unknown molecular features, and unpredictable clinical behavior, characterized by NAB2-STAT6 fusion. Hypoglycemia accompanying SFT (Doege-Potter syndrome) is an uncommon presentation. We present the cytomorphological features on biopsy imprint smears of a histopathologically confirmed case of SFT of the lung with an uncommon presentation. A 76-year-old non-smoker, non-alcoholic, and non-diabetic man presented with complaints of intermittent episodes of confusion with syncopal attacks (>10 episodes) for six months...
March 2024: Curēus
#31
Tomohito Mizuno, Yoko Endo, Atsushi Suzuki, Masashi Suzuki
Although immunoglobulin G4 (IgG4)-related kidney diseases are typically characterized by tubulointerstitial nephritis with abundant infiltration of IgG4-positive plasma cells and fibrosis, there have been relatively rare cases of IgG4-related glomerulonephritis. Several cases of IgG4-related disease (IgG4-RD) following coronavirus disease 2019 (COVID-19) mRNA vaccination have been reported. However, there are no reports of IgG4-related glomerulonephritis following COVID-19 vaccination. Herein, we present a case of IgG4-related membranous nephropathy (MN) occurring after COVID-19 vaccination...
March 2024: Curēus
#32
JOURNAL ARTICLE
Josefin Marklund, Balsam Hanna, Tao Jin, Rille Pullerits
INTRODUCTION: Idiopathic inflammatory myopathies (IIMs) encompass a diverse group of diseases characterized by considerable variability in clinical manifestations, antibody profiles, and responsiveness to immunosuppressive therapies. This study aimed to investigate the association between organ involvement and distinct myositis autoantibodies in individuals with IIM in a single-center cohort. METHODS: Patients with ICD diagnoses M33.1, M33.2, M33.9, or M609 who (1) had been tested with Euroline blot assay for myositis autoantibodies and (2) met the classification criteria of definite/probable polymyositis (PM) or dermatomyositis (DM), anti-synthetase syndrome (ASS), or inclusion body myositis (IBM) were included...
2024: Frontiers in Medicine
#33
Min Deng, Xiaoqing Li, Honghao Mu, Man Wei, Lan Sun
BACKGROUND: Lung adenocarcinoma with esophageal squamous cell carcinoma is rare and the prognosis is poor, therefore there is an urgent need to improve this situation. The objective of this study was to explore the effect of first-generation tyrosine kinase inhibitors (TKIs) in the patient of the double primary malignant tumors. CASE REPORT: We report a case of lung adenocarcinoma with esophageal squamous cell carcinoma treated by icotininb after five-year follow-up...
2024: Frontiers in Medicine
#34
Yuqing Liu, Zhenwei Chen, Lu Wang, Baizhou Li
BACKGROUND: Langerhans cell histiocytosis is a rare disease characterized by the abnormal proliferation of Langerhans cells within a single organ or multiple organs. This case report aims to improve the knowledge of the presentation of gastrointestinal Langerhans cell histiocytosis to facilitate the diagnosis and management of this rare disorder. CASE PRESENTATION: A 19-month-old female presented with repeatedly mucinous bloody stools. The abdominal ultrasound revealed a slightly enlarged spleen...
2024: Pathology Oncology Research: POR
#35
JOURNAL ARTICLE
Jim Pouliopoulos, Chris Anthony, Muhammad Imran, Robert M Graham, Jane McCrohon, Cameron Holloway, Eugene Kotlyar, Kavitha Muthiah, Anne M Keogh, Christopher S Hayward, Peter S Macdonald, Andrew Jabbour
BACKGROUND: Heart transplantation is an effective treatment for end-stage congestive heart failure, however, achieving the right balance of immunosuppression to maintain graft function while minimising adverse effects is challenging. Serial endomyocardial biopsies (EMBs) are currently the standard for rejection surveillance, despite being invasive. Replacing EMB-based surveillance with cardiac magnetic resonance (CMR)-based surveillance for acute cardiac allograft rejection has shown feasibility...
April 10, 2024: Heart, Lung & Circulation
#36
JOURNAL ARTICLE
Nikolaus John, Verena Schlintl, Teresa Sassmann, Jörg Lindenmann, Melanie Fediuk, Robert Wurm, Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch, Gudrun Absenger, Luka Brcic, Philipp J Jost, Angelika Terbuch
BACKGROUND: The use and approval of immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) depends on PD-L1 expression in the tumor tissue. Nevertheless, PD-L1 often fails to predict response to treatment. One possible explanation could be a change in PD-L1 expression during the course of the disease and the neglect of reassessment. The purpose of this study was a longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC. METHODS: We retrospectively analyzed PD-L1 expression in patients with early-stage NSCLC and subsequent relapse in preoperative samples, matched surgical specimens and biopsy samples of disease recurrence...
April 11, 2024: Journal for Immunotherapy of Cancer
#37
JOURNAL ARTICLE
Manuel Röhrich, Johanna Daum, Ewgenija Gutjahr, Anna-Maria Spektor, Frederik M Glatting, Yasemin Aylin Sahin, Hans Georg Buchholz, Jorge Hoppner, Cathrin Schroeter, Eleni Mavriopoulou, Kai Schlamp, Matthias Grott, Florian Eichhorn, Claus Peter Heußel, Hans Ulrich Kauczor, Michael Kreuter, Frederik Giesel, Mathias Schreckenberger, Hauke Winter, Uwe Haberkorn
PET using 68 Ga-labeled fibroblast activation protein (FAP) inhibitors (FAPIs) holds high potential for diagnostic imaging of various malignancies, including lung cancer (LC). However, 18 F-FDG PET is still the clinical gold standard for LC imaging. Several subtypes of LC, especially lepidic LC, are frequently 18 F-FDG PET-negative, which markedly hampers the assessment of single pulmonary lesions suggestive of LC. Here, we evaluated the diagnostic potential of static and dynamic 68 Ga-FAPI-46 PET in the 18 F-FDG-negative pulmonary lesions of 19 patients who underwent surgery or biopsy for histologic diagnosis after PET imaging...
April 11, 2024: Journal of Nuclear Medicine
#38
JOURNAL ARTICLE
Sergey S Gutor, Bradley W Richmond, Vineet Agrawal, Evan L Brittain, Ciara M Shaver, Pingsheng Wu, Taryn K Boyle, Ravinder R Mallugari, Katrina Douglas, Robert N Piana, Joyce E Johnson, Robert F Miller, John H Newman, Timothy S Blackwell, Vasiliy V Polosukhin
Exertional dyspnea has been documented in U.S. military personnel after deployment to Iraq and Afghanistan. We studied whether continued exertional dyspnea in this patient population is associated with pulmonary vascular disease (PVD). We performed detailed histomorphometry of pulmonary vasculature in 52 Veterans with biopsy-proven post-deployment respiratory syndrome (PDRS) and then recruited five of these same Veterans with continued exertional dyspnea to undergo a follow-up clinical evaluation, including symptom questionnaire, pulmonary function testing, surface echocardiography, and right heart catheterization (RHC)...
April 9, 2024: Cardiovascular Pathology: the Official Journal of the Society for Cardiovascular Pathology
#39
JOURNAL ARTICLE
Leslie Hayden, James M Lightner, Stacy Strausborger, Teri J Franks, Nora L Watson, Michael R Lewin-Smith
The role that inhaled particulate matter plays in the development of post-deployment lung disease among US service members deployed to Southwest Asia during the Global War on Terrorism has been difficult to define. There is a persistent gap in data addressing the relationship between relatively short-term (months to a few years) exposures to high levels of particulate matter during deployment and the subsequent development of adverse pulmonary outcomes. Surgical lung biopsies from deployed service members and veterans (DSMs) and non-deployed service members and veterans (NDSMs) who develop lung diseases can be analyzed to potentially identify residual deployment-specific particles and develop associations with pulmonary pathological diagnoses...
2024: PloS One
#40
JOURNAL ARTICLE
Luyun Xu, Yuanmei Chen, Jianqing Ye, Min Fan, Guibin Weng, Yongshi Shen, Zhizhong Lin, Duo Lin, Yuanji Xu, Shangyuan Feng
Lung cancer has become the leading cause of cancer-related deaths globally. However, early detection of lung cancer remains challenging, resulting in poor outcomes for the patients. Herein, we developed an optical biosensor integrating surface-enhanced Raman spectroscopy (SERS) with a catalyzed hairpin assembly (CHA) to detect circular RNA (circRNA) associated with tumor formation and progression (circSATB2). The signals of the Raman reporter were considerably enhanced by generating abundant SERS "hot spots" with a core-shell nanoprobe and 2D SERS substrate with calibration capabilities...
April 11, 2024: ACS Sensors
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
